文献速递妇科

透明细胞子宫内膜癌患者的辅助治疗:基于美国国家癌症数据库的分析

Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
PubMed 文献 · Gynecol Oncol · 2017-11-10

基于美国国家癌症数据库1998至2011年4298例非转移性透明细胞子宫内膜癌患者,评估辅助治疗及社会人口学、肿瘤因素对生存的影响。多变量分析控制分期等因素后,辅助治疗与死亡风险降低无关(p=0.26);作者提出需临床试验确定最佳辅助治疗。

要点

  • 多变量分析控制分期、保险、种族、教育、合并症评分、年龄和肿瘤大小后,辅助治疗与死亡风险降低无关(p=0.26)。
  • 单变量分析中,分期越高死亡风险越高,IVA期与I-IA期相比HR 8.59(95%CI 6.60-11.18;p<0.001)。
  • 黑人种族、公共保险、地区教育程度、更高合并症评分、年龄增长和肿瘤增大也是死亡的显著预测因素。

核心结论

  • 在该美国国家癌症数据库样本中,辅助治疗对生存无有意义的影响。
  • 鉴于该疾病的侵袭性,需要临床试验来确定非转移性透明细胞子宫内膜癌患者的最佳辅助治疗以改善临床结局。

研究设计与样本

  • 回顾性分析美国国家癌症数据库1998至2011年治疗的4298例I-IVA期透明细胞子宫内膜癌患者,采用FIGO 2009分期系统,进行单变量和多变量脆弱生存分析。
  • 辅助治疗分组包括:子宫切除术(HYS);HYS+阴道近距离放疗(VBT);HYS+化疗(CT);HYS+外照射放疗(EBRT);HYS+CT+EBRT;以及HYS+CT+VBT。

主要发现

  • 单变量分析中,与I-IA期相比,IB期死亡风险HR 1.75(95%CI 1.50-2.04;p<0.001),II期HR 1.77(95%CI 1.50-2.10;p<0.001),III-IIIB期HR 3.29(95%CI 2.86-3.80;p<0.001),IIIC-IIIC2期HR 3.33(95%CI 2.94-3.77;p<0.001),IVA期HR 8.59(95%CI 6.60-11.18;p<0.001)。
  • 其他有意义的死亡预测因素包括黑人种族(p<0.001)、公共保险(p<0.001)、地区教育程度(p=0.001)、更高合并症评分(p=0.001)、年龄增长(p<0.001)和肿瘤增大(p<0.001)。
  • 控制分期、保险、种族、教育程度、合并症评分、年龄和肿瘤大小后,辅助治疗与死亡风险降低无关(p=0.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of adjuvant treatment, sociodemographic and tumor factors on the survival of patients with non-metastatic clear cell endometrial carcinoma (CCC). METHODS: 4298 patients treated from 1998 to 2011 with Stage I-IVA CCC were identified within the National Cancer Database. FIGO 2009 staging system was used. Adjuvant groups included: hysterectomy (HYS); HYS+vaginal brachytherapy (VBT); HYS+chemotherapy (CT); HYS+external beam radiation therapy (EBRT); HYS+CT+EBRT; and HYS+CT+VBT. Univariable (UVA) and multivariable (MVA) frailty survival analyses were performed. RESULTS: On UVA, higher stage was associated with an increased risk of death. Compared to stage I-IA, the risk of death for stage IB was HR 1.75 (95% CI, 1.50-2.04; p<0.001), stage II was HR 1.77 (95% CI, 1.50-2.10; p<0.001), stage III-IIIB was HR 3.29 (95% CI, 2.86-3.80; p<0.001), stage IIIC-IIIC2 was HR 3.33 (95% CI: 2.94-3.77; p<0.001), and stage IVA was 8.59 (95% CI: 6.60-11.18; p<0.001). Other meaningful predictors of death included black race (p<0.001), public insurance (p<0.001), geographic education attainment (p=0.001), greater comorbidity score (p=0.001), increasing age (p<0.001), and increasing tumor size (p<0.001). After controlling for stage, insurance, race, education attainment, comorbidity score, age, and tumor size adjuvant treatment was not associated with decreased risk of mortality (p=0.26). CONCLUSION: Adjuvant therapy did not have a meaningful effect on survival in this sample from the National Cancer Center Database. Given the aggressive nature of the disease, clinical trials are required to determine the optimal adjuvant therapy in patients with non-metastatic CCC to improve clinical outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nieto K, Adams W, Pham N, et al. Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database. Gynecol Oncol. 2017. PMID: 29129389. doi:10.1016/j.ygyno.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。